Evaluating the immunomodulatory responses of LdODC-derived MHC Class-II restricted peptides against VL
- PMID: 31976563
- DOI: 10.1111/pim.12699
Evaluating the immunomodulatory responses of LdODC-derived MHC Class-II restricted peptides against VL
Retraction in
-
Retraction.Parasite Immunol. 2023 Jan;45(1):e12959. doi: 10.1111/pim.12959. Epub 2022 Nov 25. Parasite Immunol. 2023. PMID: 36426820
Abstract
In a bid to develop a novel immunoprophylactic measure against visceral leishmaniasis (VL), MHC class-II-restricted epitopes of LdODC were identified by reverse vaccinology approach. Five consensus HLA-DRB1*0101-restricted epitopes were screened. The analysis revealed that the set of epitopes was presented by at least 54 diverse MHC class-II alleles. Based on in silico screening, followed by molecular dynamics simulation, population coverage analysis, and HLA cross-presentation ability, five best epitopes were evaluated. PBMCs isolated from treated VL subjects, when stimulated with synthetic peptide alone or as a cocktail of peptides, triggered a secretory IFN-γ, but not the IL-10 level. Support in this notion came from intracellular cytokine level with a considerable up-regulated IFN-γ produced by CD4+ T cells. Also, the enhanced IFN-γ seemed to be augmented with the activation of macrophages with prominent IL-12 production. Therefore, it can be concluded that the screened MHC class-II-restricted epitope hotspots derived from Leishmania ODC can trigger CD4+ T cells, which can skew macrophage functions towards protection. However, a detailed analysis can explore its potentiality as a vaccine candidate.
Keywords: Leishmania donovani; CD4+ T-cell epitopes; ODC; reverse vaccinology; visceral leishmaniasis.
© 2020 John Wiley & Sons Ltd.
References
REFERENCES
-
- Dikhit MR, Kumar A, Das S, et al. Identification of potential MHC class-II-restricted epitopes derived from Leishmania donovani antigens by reverse vaccinology and evaluation of their CD4+ T-cell responsiveness. Front Immunol. 2017;8:1763.
-
- Ready PD. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 2014;6:147-154.
-
- Sundar S. Visceral leishmaniasis. Trop Parasitol. 2015;5(2):83-85.
-
- Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis. 2010;2(2):151-158.
-
- Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis. 2010;2(2):159-166.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials